MADISON, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Robert Essner, Chairman and Chief Executive Officer of Wyeth , announced today the promotion of Joseph Mahady, 53, to President - Global Business, Wyeth Pharmaceuticals and Senior Vice President, Wyeth. Mr. Mahady will continue to report to Bernard Poussot, President, Chief Operating Officer and Vice Chairman of Wyeth.
In his new role, Mr. Mahady assumes operational responsibility for Wyeth’s global pharmaceutical business, including Europe/Middle East/Africa, Asia/Pacific, and Wyeth Nutrition, in addition to his current responsibilities for the Americas and the four strategic Global Business Units - Pharmaceuticals, BioPharma, Vaccines and Women’s Health Care.
Mr. Mahady joined Wyeth in 1979 as a pharmacist in Regulatory Affairs. Following his progression through several key commercial positions, he was appointed President, U.S. in 1995. He has since assumed responsibilities for the remainder of the Americas and for the Global Business Units.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
Wyeth
CONTACT: Media: Douglas Petkus, +1-973-660-5218, or Investors: JustinVictoria, +1-973-660-5340, both of Wyeth
Web site: http://www.wyeth.com/
